ARL67156 (trisodium)

ARL67156 (FPL 67156) trisodium is a selective small is a selective samll molecular inhibitor, targeting to ecto-ATPase, CD39, and CD73. ARL67156 trisodium is also a competitive inhibitor of NTPDase1 (CD39), NTPDase3 and NPP1, with K_is of 11, 18 and 12 μM, respectively. ARL67156 trisodium can be used in the research of calcific aortic valve disease, asthma^[1][2]. IC50 & Target: Ki: 11 μM (NTPDase1), 18 μM (NTPDase3), 12 μM (NPP1)^[1] In Vitro: ARL67156 trisodium (1-100 μM) potentiates neurogenic contractions in a concentration-dependent manner^[4].
ARL67156 trisodium (10 μg/mL, 24 h) increases the surface expression of CXCR3 on ATP-treated HMC-1 cells^[5].
ARL67156 trisodium (30 μM, 5s) potentiates the norepinephrine release promoted by ATP in guinea pig heart synaptosomes^[6].
ARL67156 trisodium (100 μM, 4h) significantly decreases HIV-1replication in macrophages^[7].
In Vivo: ARL67156 trisodium (1.1 μg/kg/day, administered with osmotic pumps implanted subcutaneously, for 28 days) prevents the development of calcific aortic valve disease in Warfarin (HY-B0687)-treated rats^[2].
ARL67156 trisodium (intraperitoneal injection, 2 mg/kg) prevents the increase of serum adenosine concentration induced by Fructose 1,6-bisphosphate (FBP)^[3].